Figure 3.

Ginsenoside Rb2 inhibits the CSC‐like properties and mobility of CRC cells via EGFR signaling. HT29 (A) and SW620 (B) cells were treated with ginsenoside Rb2, and the expression levels of CSC and EMT markers were determined by RT‐qPCR. (C‐E) HT29 cells were treated with ginsenoside Rb2 and EGF at different concentrations for 24 h. Then, the phosphorylation level and total protein level of EGFR (C and D) and AKT (C and E) were determined by immunoblots. (F‐J) HT29 cells were treated with either DMSO, ginsenoside Rb2 alone or ginsenoside Rb2 together with 200 ng/mL of EGF in serum‐free media for 2 d. Then, the cells were seeded for migration assay (F and G) or RNA was extracted to determine the expression of SOX2 (H), SNAIL (I), and EGFR (J) by RT‐qPCR. The statistical analysis is shown (*, P < 0.05; **, P < 0.01). The data are presented as the mean ± SEM of three independent experiments